154 related articles for article (PubMed ID: 25497207)
1. Neurological and cardiac responses after treatment with miglustat and a ketogenic diet in a patient with Sandhoff disease.
Villamizar-Schiller IT; Pabón LA; Hufnagel SB; Serrano NC; Karl G; Jefferies JL; Hopkin RJ; Prada CE
Eur J Med Genet; 2015 Mar; 58(3):180-3. PubMed ID: 25497207
[TBL] [Abstract][Full Text] [Related]
2. Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Denny CA; Heinecke KA; Kim YP; Baek RC; Loh KS; Butters TD; Bronson RT; Platt FM; Seyfried TN
J Neurochem; 2010 Jun; 113(6):1525-35. PubMed ID: 20374428
[TBL] [Abstract][Full Text] [Related]
3. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.
Masciullo M; Santoro M; Modoni A; Ricci E; Guitton J; Tonali P; Silvestri G
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S355-61. PubMed ID: 20821051
[TBL] [Abstract][Full Text] [Related]
4. Miglustat therapy in juvenile Sandhoff disease.
Tallaksen CM; Berg JE
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S289-93. PubMed ID: 19898953
[TBL] [Abstract][Full Text] [Related]
5. Substrate deprivation therapy in juvenile Sandhoff disease.
Wortmann SB; Lefeber DJ; Dekomien G; Willemsen MA; Wevers RA; Morava E
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S307-11. PubMed ID: 19898952
[TBL] [Abstract][Full Text] [Related]
6. Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Andersson U; Smith D; Jeyakumar M; Butters TD; Borja MC; Dwek RA; Platt FM
Neurobiol Dis; 2004 Aug; 16(3):506-15. PubMed ID: 15262262
[TBL] [Abstract][Full Text] [Related]
7. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
8. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
9. Adult Sandhoff disease with 2 mutations in the HEXB gene presenting as brachial amyotrophic diplegia.
Kang SY; Song SK; Lee JS; Choi JC; Kang JH
J Clin Neuromuscul Dis; 2013 Dec; 15(2):47-51. PubMed ID: 24263030
[TBL] [Abstract][Full Text] [Related]
10. [Juvenile form of Sandhoff disease: first case reported in Argentina].
Mugnaini J; Pereyra M; Dodelson de Kremer R; Gamboni B; Argaraña CE; Oller Ramírez AM
Arch Argent Pediatr; 2017 Oct; 115(5):e298-e301. PubMed ID: 28895707
[TBL] [Abstract][Full Text] [Related]
11. Homozygous p.R284* mutation in HEXB gene causing Sandhoff disease with nystagmus.
Masri A; Liao J; Kornreich R; Haghighi A
Eur J Paediatr Neurol; 2014 May; 18(3):399-403. PubMed ID: 24613245
[TBL] [Abstract][Full Text] [Related]
12. Initiation and discontinuation of substrate inhibitor treatment in patients with Niemann-Pick type C disease.
Pérez-Poyato MS; Gordo MM; Marfa MP
Gene; 2012 Sep; 506(1):207-10. PubMed ID: 22750297
[TBL] [Abstract][Full Text] [Related]
13. Influence of caloric restriction on motor behavior, longevity, and brain lipid composition in Sandhoff disease mice.
Denny CA; Kasperzyk JL; Gorham KN; Bronson RT; Seyfried TN
J Neurosci Res; 2006 May; 83(6):1028-38. PubMed ID: 16521125
[TBL] [Abstract][Full Text] [Related]
14. NSAIDs increase survival in the Sandhoff disease mouse: synergy with N-butyldeoxynojirimycin.
Jeyakumar M; Smith DA; Williams IM; Borja MC; Neville DC; Butters TD; Dwek RA; Platt FM
Ann Neurol; 2004 Nov; 56(5):642-9. PubMed ID: 15505823
[TBL] [Abstract][Full Text] [Related]
15. Infantile gangliosidoses: Mapping a timeline of clinical changes.
Jarnes Utz JR; Kim S; King K; Ziegler R; Schema L; Redtree ES; Whitley CB
Mol Genet Metab; 2017 Jun; 121(2):170-179. PubMed ID: 28476546
[TBL] [Abstract][Full Text] [Related]
16. GM2 gangliosidoses in Spain: analysis of the HEXA and HEXB genes in 34 Tay-Sachs and 14 Sandhoff patients.
Gort L; de Olano N; Macías-Vidal J; Coll MA;
Gene; 2012 Sep; 506(1):25-30. PubMed ID: 22789865
[TBL] [Abstract][Full Text] [Related]
17. Enhanced survival in Sandhoff disease mice receiving a combination of substrate deprivation therapy and bone marrow transplantation.
Jeyakumar M; Norflus F; Tifft CJ; Cortina-Borja M; Butters TD; Proia RL; Perry VH; Dwek RA; Platt FM
Blood; 2001 Jan; 97(1):327-9. PubMed ID: 11133779
[TBL] [Abstract][Full Text] [Related]
18. New cases of adult-onset Sandhoff disease with a cerebellar or lower motor neuron phenotype.
Delnooz CC; Lefeber DJ; Langemeijer SM; Hoffjan S; Dekomien G; Zwarts MJ; Van Engelen BG; Wevers RA; Schelhaas HJ; van de Warrenburg BP
J Neurol Neurosurg Psychiatry; 2010 Sep; 81(9):968-72. PubMed ID: 20798201
[TBL] [Abstract][Full Text] [Related]
19. [Glial cells and pharmacological targets in Sandhoff disease].
Ogawa Y; Sakuraba H; Oishi K
Nihon Yakurigaku Zasshi; 2021; 156(4):235-238. PubMed ID: 34193703
[TBL] [Abstract][Full Text] [Related]
20. Characterization of seven novel mutations on the HEXB gene in French Sandhoff patients.
Gaignard P; Fagart J; Niemir N; Puech JP; Azouguene E; Dussau J; Caillaud C
Gene; 2013 Jan; 512(2):521-6. PubMed ID: 23046579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
